Sofosbuvir/Daclatasvir Matches Grazoprevir/Elbasvir at 100% SVR12 in Hemodialysis Hepatitis C

This small Indonesian trial reports universal sustained virologic response with two direct-acting antiviral regimens in hemodialysis patients, but its design flaws limit what pharmacists can conclude about comparative efficacy.

📅 Journal publication: Jul 2026 · Last updated: Oct 24, 2026

sofosbuvirdaclatasvirgrazoprevirelbasvirdirect-acting antiviralshepatitis Chemodialysischronic kidney diseaserandomised controlled trialSVR12cost Gastroenterology / Hepatology

Background Information

Sofosbuvir/daclatasvir proves effective for hepatitis C in hemodialysis patients.

Patients with hepatitis C undergoing hemodialysis need effective and safe treatment options that are also cost-effective. The study showed that 100% of patients achieved sustained virologic response at week 12 (SVR12) with both treatment regimens, with no significant adverse events reported. Both sofosbuvir/daclatasvir and grazoprevir/elbasvir are effective for hepatitis C in hemodialysis patients, but sofosbuvir/daclatasvir may offer broader applicability and lower costs. Sofosbuvir/daclatasvir is effective, safe, and cost-efficient for hepatitis C in patients on hemodialysis.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Sulaiman AS, Nugroho P, Bestari MB, Afiatin A, Akil F, Albaar A, Purnomo HD, Lestari D, Pramana TY, Susanto A, Rachmani D, Khek-Yu LH

Citation: Sulaiman AS, Nugroho P, Bestari MB, et al. Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial. Acta medica Indonesiana. 2026;58(3):415-422.

Article Links: PubMed

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →